At present, there is an unprecedented upsurge of cases of severe intrauterine infection with parvovirus B19 in northwestern Europe. Parvovirus B19 is well known as the causative agent of erythema infectiosum (also known as fifth disease), a common and ...
Obert Tanner created the Tanner Lectures in 1975 to contribute to “the moral and intellectual life” of humankind. Approaching its 50th anniversary, the program has provided a discussion space for scholars, writers, artists, and political leaders alike....
Underbelly: childhood diarrhoea and the hidden local realities of global health by Rachel Hall-Clifford is an ethnographic study examining childhood diarrhoea and its remedies in Guatemala's Mayan communities. As a Mayan child, during Guatemala's armed...
Dattwyler RJ, Arnaboldi PM. Vaccination hesistancy in Lyme borreliosis. Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4—In this Comment, the declaration of interests has been updated. This correction has b...
The RH5.1/Matrix-M vaccine candidate shows an acceptable safety and reactogenicity profile in both adults and 5–17-month-old children residing in a malaria-endemic area, with all children in the delayed third dose regimen reaching a level of GIA previo...
The high treatment success and good safety results indicate considerable potential for the use of mSTRs in programmatic conditions, especially for individuals not eligible for the current WHO-recommended 6-month regimen and in settings with a need for ...
Yearly, about 410 000 patients worldwide develop rifampicin-resistant tuberculosis, resistant to the most powerful first-line tuberculosis drug. In 2012, treatment for rifampicin-resistant tuberculosis constituted mainly regimens of 18 months or longer...
In The Lancet Infectious Diseases, Sarah E Silk and colleagues1 present advances in the clinical development of the leading blood-stage malaria vaccine candidate. A collaboration between UK and Tanzanian investigators, the authors report the first-in-h...
Avian influenza virus continues to pose zoonotic, epizootic, and pandemic threats worldwide, as exemplified by the 2020–23 epizootics of re-emerging H5 genotype avian influenza viruses among birds and mammals and the fatal jump to humans of emerging A(...
Cholera remains a global threat to health security, particularly in sub-Saharan Africa where outbreaks have become frequent, with increased magnitude and fatalities.1,2 While the world is preparing for the next pandemic, we explored clinical outcomes a...
As of May 30, 2024, three people have been diagnosed with a highly pathogenic avian influenza A(H5N1) virus currently circulating in cattle in the USA. Talha Burki reports.
We have an ethical imperative to learn from recent influenza H1N1 and COVID-19 pandemics to better prepare for the next one. WHO has highlighted the need for surveillance frameworks that can be implemented across states.1 For any future epidemic or pan...
Lyme borreliosis is the most common vector borne infectious disease in North America and Europe and both its incidence and the geographical range of endemic areas are increasing.1–3 Lyme borreliosis is a systemic infectious disease that can affect mult...
VLA15 was safe, well tolerated, and elicited robust antibody responses to all six OspA serotypes. These findings support further clinical development of VLA15 using the 180 μg dose and 0-2-6-month schedule, which was associated with the greatest immune...
Long-acting therapy had non-inferior efficacy compared with oral therapy, with a good safety profile, and can be considered for African treatment programmes.
Cabotegravir and rilpivirine as a complete long-acting injectable regimen is recommended in international guidelines in virologically suppressed adults for maintenance therapy, as an alternative to daily oral therapy.1–3 Most guidelines cite improved q...